Pages that link to "Q43241188"
Jump to navigation
Jump to search
The following pages link to Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation (Q43241188):
Displaying 13 items.
- Therapeutic apheresis before and after kidney transplantation (Q30454250) (← links)
- Therapeutic apheresis in renal transplantation; current practices (Q30458220) (← links)
- Rational clinical trial design for antibody mediated renal allograft injury. (Q36173541) (← links)
- The yin and yang of B cells in graft rejection and tolerance (Q37690953) (← links)
- Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach (Q37820338) (← links)
- Antibody-mediated rejection in kidney transplantation: an update (Q37835834) (← links)
- Prevention and treatment of alloantibody-mediated kidney transplant rejection (Q37914943) (← links)
- Apheresis therapy in children: an overview of key technical aspects and a review of experience in pediatric renal disease (Q38082735) (← links)
- Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013. (Q38118112) (← links)
- Summary of FDA Antibody-Mediated Rejection Workshop (Q42598786) (← links)
- Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. (Q53591741) (← links)
- Therapeutic Apheresis for Renal Disorders (Q83688292) (← links)
- Comparing Plasmapheresis plus IVIg with Plasmapheresis plus IVIg plus Rituximab on the Management of Suspicious Antibody-Mediated Acute Rejection in Kidney Transplant Recipients (Q93188012) (← links)